Mariana I Nelson

US Patent:

20150125451, May 7, 2015

Filed:

Mar 14, 2013

Appl. No.:

14/398020

Inventors:

- Eagan MN, US
Mary A. Antonysamy - Woodbury MN, US
Richard M. Walsh - Lino Lakes MN, US
Mariana I. Nelson - Rosemount MN, US
Nandita Bose - Plymouth MN, US
Michael E. Danielson - St. Paul MN, US
Kyle S. Michel - Eagan MN, US

Assignee:

Biothera, Inc. - Eagan MN

International Classification:

A61K 39/395
A61K 47/48
A61K 39/39

US Classification:

4241371, 4241781

Abstract:

This disclosure describes, in one aspect, a composition that includes a β-glucan component and an antibody component that specifically binds to the β-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to β-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of β-glucan and administering to the subject a composition that comprises a β-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.

US Patent:

20150125461, May 7, 2015

Filed:

Mar 14, 2013

Appl. No.:

14/398019

Inventors:

- Eagan MN, US
Mary A. Antonysamy - Woodbury MN, US
Richard M. Walsh - Lino Lakes MN, US
Mariana I. Nelson - Rosemount MN, US
Nandita Bose - Plymouth MN, US
Michael E. Danielson - St. Paul MN, US
Kyle S. Michel - Eagan MN, US

Assignee:

Biothera, Inc. - Eagan MN

International Classification:

A61K 39/395
A61K 31/716
G01N 33/569

US Classification:

4241411, 435 792, 435 71, 4241301

Abstract:

This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.